GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Procaps Group SA (NAS:PROC) » Definitions » Cash Ratio

Procaps Group (Procaps Group) Cash Ratio : 0.13 (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Procaps Group Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Procaps Group's Cash Ratio for the quarter that ended in Sep. 2023 was 0.13.

Procaps Group has a Cash Ratio of 0.13. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for Procaps Group's Cash Ratio or its related term are showing as below:

PROC' s Cash Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.12   Max: 0.38
Current: 0.13

During the past 4 years, Procaps Group's highest Cash Ratio was 0.38. The lowest was 0.01. And the median was 0.12.

PROC's Cash Ratio is ranked worse than
81.28% of 1031 companies
in the Drug Manufacturers industry
Industry Median: 0.58 vs PROC: 0.13

Procaps Group Cash Ratio Historical Data

The historical data trend for Procaps Group's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Procaps Group Cash Ratio Chart

Procaps Group Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Cash Ratio
0.01 0.02 0.38 0.12

Procaps Group Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.12 0.10 0.08 0.13

Competitive Comparison of Procaps Group's Cash Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Procaps Group's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Procaps Group's Cash Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Procaps Group's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Procaps Group's Cash Ratio falls into.



Procaps Group Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Procaps Group's Cash Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash Ratio (A: Dec. 2022 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=43.003/368.374
=0.12

Procaps Group's Cash Ratio for the quarter that ended in Sep. 2023 is calculated as:

Cash Ratio (Q: Sep. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=25.831/202.93
=0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Procaps Group  (NAS:PROC) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Procaps Group Cash Ratio Related Terms

Thank you for viewing the detailed overview of Procaps Group's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Procaps Group (Procaps Group) Business Description

Traded in Other Exchanges
Address
9 Rue de Bitbourg, Luxembourg, LUX, L-1273
Procaps Group SA is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. It develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements, and high-potency clinical solutions. The company's segment includes NextGel; Procaps Colombia; CAN; CASAND and Diabetrics. It generates maximum revenue from the Procaps Colombia segment.
Executives
Alexandre Weinstein Manieu director, 10 percent owner CHASHAM PLACE, FLAT 1, LONDON X0 SW1X 8HG
Ruben Minski director, 10 percent owner, officer: Chief Executive Officer 9 RUE DE BITBOURG, C/O PROCAPS GROUP, S.A., LUXEMBOURG N4 L-1273
Jose Minski director, 10 percent owner 9 RUE DE BITBOURG, C/O PROCAPS GROUP, S.A., LUXEMBOURG N4 L-1273
Sognatore Trust 10 percent owner OFICINA 503A-02, EDIFICIO QUANTUM, (500) RUTA 8 KM. 17.500 ZONAMERICA, MONTEVIDEO X3 91600
Simphony Trust 10 percent owner 29 BANCROFT MILLS ROAD, WILMINGTON DE 19806
Deseja Trust 10 percent owner 29 BANCROFT MILLS ROAD, WILMINGTON DE 19806
Hoche Partners Pharma Holding S.a. 10 percent owner 3A VAL SAINTE CROIX, LUXEMBOURG N4 L-1371